Enterprise Value

140M

Cash

80.64M

Avg Qtr Burn

-58.66M

Short % of Float

11.98%

Insider Ownership

0.89%

Institutional Own.

0.64%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
SP-102 (SEMDEXA™) Details
Sciatica , Spine disorder

NDA

FDA meeting

STI-5656 (Abivertinib Maleate) (BTK and EGFR inhibitor) Details
Lung disease, Lung cancer, Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Phase 3

Initiation

SP-103 Details
Chronic lower back pain

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 1

Data readout

Abivertinib Maleate (Fujovee) (STI-5656) (BTK inhibitor) Details
Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

STI-2020 (COVI-AMG) Details
COVID-19, Solid tumor/s

Failed

Discontinued